Blocking complement with the humanized anti-C5 monoclonal antibody eculizumab is very good at reducing intravascular hemolysis, lowering the risk of thrombosis, and lowering the need for transfusions, all of which improve quality of life. This evidence concerns the gene C5 and hemolysis.